Press Releases

2022

20 October, 2022
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial 

08 ApRil, 2022
T-knife Therapeutics Announces New TCR-T Program Targeting KRAS ^G12V and Presents Data at the American Association for Cancer Research (AACR) Annual Meeting

05 Jan, 2022
T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel

2021

30 Nov, 2021
T-knife Therapeutics Appoints Biotech Industry Veteran Laura Brege to its Board of Directors

15 Nov 2021
T-knife Therapeutics Reports Preclinical Efficacy Data Induced by TK-8001, a Novel MAGE-A1-Specific TCR-T

01 OCT, 2021
T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

04 AUG, 2021
T-knife Therapeutics Appoints Peggy Sotiropoulou, Ph.D. as Chief Scientific Officer

02 AUG, 2021
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

12 JUL, 2021
T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer

07 APR, 2021
T-knife Therapeutics Announces the Appointment of Donald Wuchterl as Senior Vice President and Chief Manufacturing Officer

19 JAN, 2021
T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer

2020

21 SEP, 2020
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy